The OPERA study: The tenor or baritone of shorter duration of DAPT?
J. Warren,R. Mehran
DOI: https://doi.org/10.1002/ccd.25604
IF: 2.3
2014-09-01
Catheterization and Cardiovascular Interventions
Abstract:Establishing the optimal duration of dual antiplatelet therapy (DAPT) following intracoronary stent implantation has attracted increasing focus over recent years. DAPT, which refers to the combination of aspirin coupled with an inhibitor of the platelet adenosine diphosphate P2Y12 receptor, forms the cornerstone of secondary prevention following stent implantation. The optimal duration of therapy remains to be established. Following the unexpectedly high rates of stent thrombosis associated with first generation drug eluting stents (DES), clinical guidelines were altered to advocate longer DAPT durations to reflect and mitigate thrombotic risk. However, the risk of increased bleeding events associated with prolonged DAPT has led to the hypothesis that reduced DAPT duration may be more safe and effective, particularly with newer second generation DES. At present, clinical guidelines recommend the use of DAPT for a minimum of 6–12 months following DES implantation, but this can vary according to clinical indication, bleeding risk, and country of practice [1–3]. In light of promising results from earlier large-scale observational studies, several randomized trials have demonstrated that short DAPT durations may be safer without compromising anti-ischemic efficacy [4]. However, these studies are not without limitation, which include nonuniformity of stent selection, insufficient power to demonstrate reduction in individual ischemic events, and exclusion criteria that preclude the enrollment of patients with high risk presentations, thereby limiting the external validity of findings. The current study is a prospective, nonrandomized, multicenter study comparing 3and 12-month DAPT exclusively in patients receiving Endeavor zotarolimuseluting stents (E-ZES). The principal aim is to demonstrate noninferiority in the 3-month DAPT group in terms of the primary endpoint of 12-month net adverse clinical and cerebrovascular events (NACCE), which includes death, non-Q-wave myocardial infarction (MI), Q-wave MI, cerebrovascular accident, and major bleeding. The uniform use of E-ZES across both study arms ensures consistency between stent platforms, design, and antiproliferative agent characteristics. Furthermore, the “all-comers” enrolment design enhances generalizability, while also permitting sufficient patient numbers to demonstrate noninferiority across study endpoints. The Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor [Zotarolimus-Eluting Stent] in Real-World Japanese Patients with Coronary Artery Disease (OPERA) study bears similarity to the OPTIMIZE trial, which also compared 3 and 12month DAPT using ZES [5]. Though the studies examined similar patient numbers and composite endpoints, the OPTIMIZE trial was randomized, and largely consisted of patients with either stable angina or low risk acute coronary syndrome. The OPERA study will provide complementary data on a wider spectrum of patients in a more “real-world” setting. It is also worth noting that the two study arms are extracted from two different databases and enroll patients over separate timeframes, which may limit the direct comparison between groups. The exclusive use of clopidogrel as the thienopyridine precludes the potential to explore the efficacy of the newer antiplatelet agents in shorter durations, an area which requires further exploration. Analogously, extrapolating results from this study to other newer generation